Reduction in death seen at 28, 60 days for patients receiving invasive mechanical ventilation, extracorporeal membrane oxygenation
Your search for baricitinib returned 48 results
Based on efficacy results from 2 phase 3 studies, Lilly has decided to discontinue development of baricitinib for lupus.
But placebo-controlled trial shows lower all-cause mortality at 28 days and 60 days in patients receiving baricitinib plus standard of care
The update was based on data from the COV-BARRIER study.
Long-term sustained outcomes seen among adults with moderate-to-severe atopic dermatitis
Results from 2 studies show statistically significant improvement in scalp hair regrowth with baricitinib, a JAK inhibitor.
Findings showed that the trial did not meet statistical significance on the primary endpoint.
Both doses of baricitinib met the primary end point, demonstrating statistically significant improvement in scalp hair regrowth compared with placebo.
The EUA was granted based on data from the phase 3 ACTT-2 trial, which was conducted by the NIAID.
The ACTT-2 study began on May 8 and included more than 1000 patients.